This disclosure features combinations of NMDAR modulating compounds. This disclosure features combinations that include one or mor NMDAR antagonists and GLYX 13 (each of which is sometimes referred to herein as a component). The beneficial effects of the combination are based in part on the finding that administration of GLYX 13 (e.g. a single dose) can reverse and/or prevent NMDAR antagonist induced cognitive impairment (e.g. NMDAR antagonist induced impairment in novel object recognition e.g. induced through repeated dosing of the NMDAR antagonist).
